The content on this site is intended for healthcare professionals only
Prof Nabid talks to ecancertv at ASCO GU 2015 about the results of a phase III study examining the "controversial" role of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Management of prostate cancer in Africa: Looking to the future
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC
![Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )](https://cdn.ecancer.org/44737-m.jpg)
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer
Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men
Single intensive screening intervention using PSA and Stockholm3 in combination might reduce prostate cancer mortality
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
